- Exact Sciences to participate in August investor conference
- Exact Sciences Announces Second Quarter 2020 Results
- Exact Sciences schedules annual meeting, second quarter 2020 earnings call
- Oncotype DX Genomic Prostate Score® Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfavorable Intermediate-Risk Prostate Cancer Patients
- Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020
- New Data and Society Guidelines Support Value of Oncotype DX Breast Recurrence Score® Test in Guiding Neoadjuvant Treatment Decisions for Newly Diagnosed Patients
- Exact Sciences to participate in June investor conferences
- New Oncotype DX® Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results
Exact Sciences Corp (EXAS:NAQ) closed at 86.69, -29.70% below its 52-week high of 123.31, set on Aug 29, 2019.
35.25Mar 18 2020123.31Aug 29 2019
Markit short selling activity
|Market cap||13.02bn USD|
|EPS (TTM)||-1.04 |
Data delayed at least 15 minutes, as of Aug 07 2020 21:00 BST.